Recent developments in the pharmacological treatment and prevention of corneal graft rejection

Authors: Banerjee S.; Dick A.D.

Source: Expert Opinion on Investigational Drugs, Volume 12, Number 1, 1 January 2003 , pp. 29-37(9)

Publisher: Informa Healthcare

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

At present, given the high initial success rate of corneal transplantation (although late survival is poor), immunosuppression is often reserved for ‘high-risk’ patients. Despite immune privilege, corneal graft rejection remains the leading cause of corneal allograft failure. Interpreting the limited and also restricted design of most trials, immunosuppressive therapy has not enjoyed the success seen in solid organ grafts. This review discusses the limited data available whilst proposing newer therapies that have developed as a result of our increased understanding of the immunobiology of corneal graft rejection.

Keywords: corneal transplantation; corticosteroids; cyclosporin A; immunosuppressants; mAb therapies; mycophenolate mofetil; tacrolimus

Document Type: Review article

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$99.00 plus tax Refund Policy